Estrella Immunopharma (ESLA) Stock Price, News & Analysis

Company Overview

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Key Stats

• Today's Range: $0.94 to $1.05
• 50-Day Range: $0.76 to $1.16
• 52-Week Range: $0.63 to $3.23
• Volume: 13,638 shs
• Average Volume: 85,539 shs
• Market Capitalization: $35.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.00
• Consensus Rating: Buy

Estrella Immunopharma Stock Analysis - MarketRank™

Estrella Immunopharma scored higher than 51% of companies evaluated by MarketBeat, and ranked 548th out of 924 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Estrella Immunopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Estrella Immunopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Estrella Immunopharma is -3.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Estrella Immunopharma is -3.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Estrella Immunopharma has a P/B Ratio of 8.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.21% of the float of Estrella Immunopharma has been sold short.

Short Interest Ratio / Days to Cover

Estrella Immunopharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Estrella Immunopharma has recently increased by 1,021.05%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Estrella Immunopharma does not currently pay a dividend.

Dividend Growth

Estrella Immunopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.21% of the float of Estrella Immunopharma has been sold short.

Short Interest Ratio / Days to Cover

Estrella Immunopharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Estrella Immunopharma has recently increased by 1,021.05%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: N/A

News Sentiment

Estrella Immunopharma has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Estrella Immunopharma this week, compared to 0 articles on an average week.

Search Interest

2 people have searched for ESLA on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Estrella Immunopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

55.10% of the stock of Estrella Immunopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 0.35% of the stock of Estrella Immunopharma is held by institutions.

ESLA Stock Analysis - Frequently Asked Questions

How have ESLA shares performed this year?

Estrella Immunopharma's stock was trading at $1.20 at the start of the year. Since then, ESLA shares have decreased by 17.5% and is now trading at $0.99.
View the best growth stocks for 2025 here.

How do I buy shares of Estrella Immunopharma?

Shares of ESLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Estrella Immunopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Estrella Immunopharma investors own include NuCana (NCNA), Cardio Diagnostics (CDIO), Caribou Biosciences (CRBU), GRI Bio (GRI), Intrusion (INTZ), Lonestar Resources US (LONE) and Children's Place (PLCE).

Company Calendar

• Today: 5/14/2025
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ESLA
• CIK: 1844417
• Web: www.estrellabio.com
• Phone: 510-318-9098
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $16.00
• High Stock Price Target: $16.00
• Low Stock Price Target: $16.00
• Potential Upside/Downside: +1,423.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-7,310,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -195.77%
• Return on Assets: -157.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.75
• Quick Ratio: 0.75

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.12 per share
• Price / Book: 8.75

Miscellaneous

• Outstanding Shares: 36,166,000
• Free Float: 16,244,000
• Market Cap: $37.97 million
• Optionable: Not Optionable
• Beta: 0.41